Thu, Apr 24, 2014, 9:03 AM EDT - U.S. Markets open in 27 mins.

Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

kgrichard5 132 posts  |  Last Activity: Apr 22, 2014 3:32 PM Member since: Feb 9, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • kgrichard5 kgrichard5 Apr 22, 2014 3:32 PM Flag

    Mensa, I appreciate your posts and will take your word as to your experience/knowledge in biotech/Pharma (especially since we share many of the same investments : ). I also worked for Pfizer and others. What are your thoughts on this biotech portfolio:
    SRPT...Heavy
    RNN...Heavy
    MSTX...Heavy
    MACK...Light
    CLDX...Medium
    CTSO...Heavy (device)
    ONCS...Heavy
    IDRA....Light
    OPRX....like a sample MD...Medium
    CUR....medium
    ACRX...Heavy
    TIA

  • kgrichard5 by kgrichard5 Apr 21, 2014 4:22 PM Flag

    and have been on the sidelines for a few years. Every time I look at this pipeline and corresponding pps, I simply shake my head in disbelief. If one of my other biotech's produce a significant gain, I may divest back into SPPI. I hope all long ago long time longs are doing well.

  • Reply to

    Up 75% on announcement SRPT!! CTSO next??

    by andy55q Apr 21, 2014 8:05 AM
    kgrichard5 kgrichard5 Apr 21, 2014 4:17 PM Flag

    I would do your own DD obviously. I will add MACK and CLDX also. What I like about all of these, including CTSO, is the breadth and depth of their pipelines. If you hold all of them for 2 plus years, then the current prices are good entries though I cannot say they are at the bottom. The recent IBB sell off has allowed for a nice pps entry. For instance, CLDX is almost 1/2 of it's 52 week high. Go to CLDX, RNN and MACK company sites and click on their pipeline tabs. MSTX not quite as rich, but good. CTSO will also have close to 10 products...I like multiple shots on goal, in unmet disease states and multiple applications per product/device. ONCS, if validated in melanoma will become a delivery system for multiple tumors. Finally, I am not selling any SRPT until 60 pps and only 10 to 25% of my holdings at that. Looks like we will be celebrating, or crying in our beer together as we hold ONCS, SRPT and CTSO together. GLTY

  • kgrichard5 kgrichard5 Apr 21, 2014 3:29 PM Flag

    Your post reveals multiple ID's...not that I care, just letting you know, in case you do.

  • Reply to

    Up 75% on announcement SRPT!! CTSO next??

    by andy55q Apr 21, 2014 8:05 AM
    kgrichard5 kgrichard5 Apr 21, 2014 3:20 PM Flag

    Congrats to you fieb57. SRPT is my largest holding (12 plus years for me as well), with CTSO close behind. You bring up a great point, Chris G. and Chan do put me in mind of each other. Take a look at RNN, ONCS and MSTX for the long term. GLTY

  • Reply to

    Congrats to families and Convicted LONGS!

    by kgrichard5 Apr 21, 2014 9:38 AM
    kgrichard5 kgrichard5 Apr 21, 2014 10:04 AM Flag

    Of course my money is in it...because I believe... and have been in this stock and done my DD for over twelve years. OK, I'll invest in something I don't believe in...great advice.

  • Reply to

    "Proprietary Drug Discovery"

    by lincoln2424 Apr 21, 2014 9:50 AM
    kgrichard5 kgrichard5 Apr 21, 2014 9:55 AM Flag

    Agree. Validation = Expansion

  • Reply to

    Congrats to families and Convicted LONGS!

    by kgrichard5 Apr 21, 2014 9:38 AM
    kgrichard5 kgrichard5 Apr 21, 2014 9:51 AM Flag

    This is great news. Spin it how you want. This opens the door for many exons and related disease states. This technology is safe and effective....that is my belief.

  • Look at SRPT for DMD this a.m. on only 12 patients. The FDA is demonstrating flexibility with compelling efficacy and safety data....even in smaller phase 2 trials. This should be an eye opener for CUR and it's various platforms...especially ALS.

  • May many disease states prosper over the coming years... one exon at a time!!

  • Reply to

    Filters are very resonable 500 dollars each !!!

    by paulnessss Apr 16, 2014 11:28 PM
    kgrichard5 kgrichard5 Apr 18, 2014 9:44 AM Flag

    Chan refers to a blade to razor CTSO filters to the applicable device. Easy to learn and use by both nurses and doctors.

  • Reply to

    Reminder of some important catylist dates....

    by waitforit52 Apr 16, 2014 1:12 PM
    kgrichard5 kgrichard5 Apr 16, 2014 3:40 PM Flag

    Exactly! This presentation seems to confirm ASCO.

    JUNE 27, 2014:
    OncoSec (ONCS)June 26-27th, 2014 4th European Post Chicago Melanoma/ Skin Cancer Meeting
    Results and Interpretations of ASCO presentations 2014
    (Global confernce on news in melanoma/skin cancer)

  • Reply to

    I am not for a Buyout

    by kgrichard5 Apr 16, 2014 3:03 PM
    kgrichard5 kgrichard5 Apr 16, 2014 3:19 PM Flag

    Agreed. I have a feeling you and I are not in this for .44, though I would be happy if were sitting there today.

  • kgrichard5 by kgrichard5 Apr 16, 2014 3:03 PM Flag

    as this company is on track for solo success. However, I cannot deny the possibility of a larger company adding all of the IP (5 to 10 products) to their portfolio and pipeline. Again, it is simply not 5 to 10 products, but the multiple applications built into each product....making them worth an IP X 20 or 30. All the dirty work and validation will be accomplished. A JNJ size company could swallow this without a hick up and prosper disproportionately in just a few years, especially with their reputation and size of sales and distribution. Hope this does not happen for at least a few years.

  • Reply to

    The real deal

    by zwerp2000 Apr 16, 2014 2:07 PM
    kgrichard5 kgrichard5 Apr 16, 2014 2:54 PM Flag

    Either way....getting a phase 3 started as soon as possible with an FDA SPA is paramount. If this is in parallel with a pending AA or needed for NDA down the road, the sooner the better for these kids and families'. As I have stated before, whether this is a conventional (pivotal) phase 3 or a confirmatory with concurrent AA, the drug will be approved. If conventional, you might as well call it AA confirmatory...because as with ICPT, the interim data will not allow wasted time to reach the masses. The drug will speak for itself with more participants showing unprecedented efficacy and safety in an unmet need that is guaranteed to deteriorate and eliminate innocent little lives. I have 3 boys, this hits home!

  • Reply to

    Merriman Conference event !!!

    by avcfineart Apr 16, 2014 10:22 AM
    kgrichard5 kgrichard5 Apr 16, 2014 11:16 AM Flag

    Multi-billion not million

  • Reply to

    Merriman Conference event !!!

    by avcfineart Apr 16, 2014 10:22 AM
    kgrichard5 kgrichard5 Apr 16, 2014 11:14 AM Flag

    If you have been long for months or years....this is one of the best utilized 22 minutes of DD you can incorporate into your busy days schedule. 5 to 10 products, multiple potential applications and partnerships...Universities, companies, military, Government....in multi-million dollar unmet needs markets. Sorry, on a pumping brigade!

  • Reply to

    Merriman Presentation

    by kgrichard5 Apr 16, 2014 10:49 AM
    kgrichard5 kgrichard5 Apr 16, 2014 10:53 AM Flag

    Forgot, As another poster has stated, CABG trial feedback is positive.

  • kgrichard5 by kgrichard5 Apr 16, 2014 10:49 AM Flag

    A must listen to for all CTSO investors:.
    2/3 of 2013 sales in Q1 2014 product sales
    Five products developed and five more significant products yet to be disclosed soon.
    Exponential sales trajectory mentioned millions and 10's of millions in sales for 2014 and beyond
    Extremely confident and excited in his delivery
    !00 billion immuno market....20 billion unmet needs segment....500 million CABG (in trial and potentially 50 to 100 million for this application alone) only 10 TO 20% MARKET SHARE. Product could be available in less than 2 years. Improvement in organ damage parameters post surgery as primary end point...not motality outcomes.

    30 ongoing clinical trials...some funded by Governmental (NIH) and military (US Army and Air Force)
    Has Already met with Nasdaq and NYSE...hope to execute up list this year following operational momentum and upcoming catalysts.
    4.5 million cash burn projection for 2014...Cash good for next two years via revenues, grants etc...
    Many revenue multipliers to create additional synergy
    Biocon partner...equated as the Amgen of India
    2014 influx of additional institutional investors
    Medical schools partnered with CTSO (Havard, MIT) after extensive search..selected CTSO
    Anticipated increased strategic partnerships
    Much more...fingers are tired..i BOUGHT MORE TODAY ..GLTA and sorry for typo's, sentence structure..was in a hurry...back to real job.

  • kgrichard5 by kgrichard5 Apr 15, 2014 2:24 PM Flag

    for the validation of electroporation.....potentially....for many many solid tumors. Today's sell off does not change the prospects of break through science and technology in an unmet disease states. .515 and .53...many thanks for the LONG term.

ONCS
0.76Apr 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.